Fair and cost-conscious allocation of omalizumab, a groundbreaking food allergy therapy.
Ann Allergy Asthma Immunol
; 133(1): 18-19, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38960561
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Anti-Allergic Agents
/
Omalizumab
/
Food Hypersensitivity
Limits:
Humans
Language:
En
Journal:
Ann Allergy Asthma Immunol
Journal subject:
ALERGIA E IMUNOLOGIA
Year:
2024
Document type:
Article